je.st
news
Tag: cardiovascular
05.23.12 -- Study Reveals Biological Link Between Air Pollution, Cardiovascular Disease
2016-06-13 17:37:22| pollutiononline Home Page
05/23/12 Pollution Online Newsletter
Can alcohol reduce the risk of cardiovascular disease? - International Scientific Forum on Alcohol Research Critique 177
2015-12-21 14:47:00| Daily beverage news and comment - from just-drinks.com
While there have been many observational studies of the relation of alcohol consumption to health risks and benefits, the number of clinical trials of alcohol administration for its health effects are limited.
Tags: forum
international
research
risk
Philips Introduces IntelliSpace Cardiovascular at ESC Congress 2015
2015-09-04 12:31:13| Industrial Newsroom - All News for Today
ANDOVER, Massachusetts and LONDON - Connected cardiology solution provides holistic view of patient care across the entire cardiovascular journey Royal Philips [http://www.usa.philips.com (NYSE: PHG, AEX: PHIA) today announced the European debut of IntelliSpace Cardiovascular...
Tags: philips
congress
introduces
cardiovascular
New Analyses from the IMPROVE-IT Outcomes Study of VYTORIN (ezetimibe and simvastatin) and the TECOS Cardiovascular Safety Trial of JANUVIA (sitagliptin) Will Be Presented at the European Society of Cardiology Congress
2015-08-20 14:30:00| Merck.com - Product News
Dateline City: KENILWORTH, N.J. Additional Real-World Analyses from DYSIS and DYSIS II Assessing the Treatment of Dyslipidemia to be Presented KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that new analyses from the investigational IMPROVE-IT (IMProved Reduction of Outcomes: VYTORIN Efficacy International Trial) study of VYTORIN (ezetimibe and simvastatin), the TECOS (Trial Evaluating Cardiovascular Outcomes with Sitagliptin) cardiovascular safety trial of JANUVIA (sitagliptin), and real-world data from the Dyslipidemia International Study (DYSIS I and DYSIS II) will be presented at the upcoming European Socie Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558orKim Hamilton, 908-391-0131orInvestor:Justin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
AstraZeneca And Isis Pharmaceuticals To Discover And Develop Antisense Drugs For Cardiovascular, Metabolic And Renal Diseases
2015-08-04 03:27:28| drugdiscoveryonline News Articles
Isis Pharmaceuticals, Inc. (NASDAQ:ISIS) and AstraZeneca today announced a strategic collaboration to discover and develop antisense therapies for cardiovascular, metabolic and renal diseases.
Tags: develop
discover
drugs
diseases
Sites : [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] next »